Neurological Clinic
Faculty of Medicine
Universitätsklinikum St. Josef-Hospital Bochum
Gudrunstr. 56
44791 Bochum
Phone:
+49 (0)234 509-2410
Email:
ralf.gold@ruhr-uni-bochum.de
We are investigating basic mechanisms that underlie the autoimmune attack, demyelination and axonal loss in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS). We aim at achieving a better understanding of therapeutic options to improve treatment of MS.
In the last years magnetic resonance imaging (MRI) has made substantial contributions for diagnosis and therapy follow-up of MS patients. It allows for a non-invasive and continuous monitoring of disease activity.
We will perform human MS studies at the 3T MRI scanner of the research department, and increasingly study EAE in mouse mutants. There we will focus on development and reorganisation of inflammatory CNS lesions in long-term follow-up studies. In particular MRI data will be correlated with histology and clinical data. Via cell tracers the fate of injected cellular subpopulations can be studied in detail. Our special focus is on neurodegenerative aspects of MS. Here we have recently made substantial contributions by studying conditional neurotrophin k.o. mice and antioxidative neuroprotection by fumarates. These measures may have relevance for further development of translational therapies.
Haghikia, A., Zimmermann, F., Schumann, P., Jasina, A., Roessler, J., Schmidt, D., Heinze, P., Kaisler, J., Nageswaran, V., Aigner, A., Ceglarek, U., Cineus, R., Hegazy, A. N., van der Vorst, E. P. C., Döring, Y., Strauch, C. M., Nemet, I., Tremaroli, V., Dwibedi, C., Gold, R.,. . . Landmesser, U. (2022). Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. European Heart Journal, 43(6), 518–533. https://doi.org/10.1093/eurheartj/ehab644
Duscha, A., Gisevius, B., Hirschberg, S., Yissachar, N., Stangl, G. I., Dawin, E., Bader, V., Haase, S., Kaisler, J., David, C., Schneider, R., Troisi, R., Zent, D., Hegelmaier, T., Dokalis, N., Gerstein, S., Del Mare-Roumani, S., Amidror, S., Staszewski, O., Gold, R., . . . Haghikia, A. (2020). Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism. Cell, 180(6), 1067-1080.e16. https://doi.org/10.1016/j.cell.2020.02.035
Gold, R., Giovannoni, G., Selmaj, K., Havrdova, E., Montalban, X., Radue, E.‑W., Stefoski, D., Robinson, R., Riester, K., Rana, J., Elkins, J., & O'Neill, G. (2013). Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): A randomised, double-blind, placebo-controlled trial. Lancet (London, England), 381(9884), 2167–2175. https://doi.org/10.1016/S0140-6736(12)62190-4
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., & Dawson, K. T. (2012). Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. The New England Journal of Medicine, 367(12), 1098–1107. https://doi.org/10.1056/NEJMoa1114287
Linker, R. A., Lee, D.‑H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., Ellrichmann, G., Brück, W., Dawson, K., Goelz, S., Wiese, S., Scannevin, R. H., Lukashev, M., & Gold, R. (2011). Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain: A Journal of Neurology, 134(Pt 3), 678–692. https://doi.org/10.1093/brain/awq386
Wenning, W., Haghikia, A., Laubenberger, J., Clifford, D. B., Behrens, P. F., Chan, A., & Gold, R. (2009). Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. The New England Journal of Medicine, 361(11), 1075–1080. https://doi.org/10.1056/NEJMoa0810257
Gold, R., Stangel, M., & Dalakas, M. C. (2007). Drug Insight: The use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues. Nature Clinical Practice. Neurology, 3(1), 36–44. https://doi.org/10.1038/ncpneuro0376
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.‑H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005). Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. The Journal of Experimental Medicine, 202(3), 445–455. https://doi.org/10.1084/jem.20051060
Linker, R. A., Mäurer, M., Gaupp, S., Martini, R., Holtmann, B., Giess, R., Rieckmann, P., Lassmann, H., Toyka, K. V., Sendtner, M., & Gold, R. (2002). Cntf is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nature Medicine, 8(6), 620–624. https://doi.org/10.1038/nm0602-620
Copyright © RDN 2024
Last update: Feb 07, 2024
